



25 Sept 2014

Market Announcement Office
Australian Securities Exchange
Level 6, 20 Bridge Street
SYDNEY NSW 2000

Dear Sir,

Appointment as a Medtech Accelerator

We are pleased to announce that the Group's wholly owned subsidiary, Zicom MedTacc Pte Ltd (MedTacc), has been appointed a Medtech Accelerator by SPRING Singapore (SPRING), a Government's agency responsible for enterprise development.

As an appointed Medtech Accelerator, SPRING Singapore will co-invest with MedTacc on growth phase medtech start-ups over the next 4 years on 1:1 basis. MedTacc and SPRING shall commit S\$15m each making a total available investment pool of S\$30m.

When start-ups enter growth phases, their risk profile improves. Coupled with SPRING's co-investment, the risks typical to such investments would be further mitigated for MedTacc.

Under the Scheme, SPRING would grant options to MedTacc to acquire their investments at nominal compound rates per year in the event the investments prove commercially viable and value may be unlocked.

The Group's investments on such growth phase start-ups will come from internal resources without any negative impact expected on its existing businesses. No bank borrowings are intended.

The Scheme aligns with the Group's directions to increase its focus on investments in technology. No immediate impact on the Group's profitability is expected. However we believe significant benefits could accrue in the medium to long term.

Yours faithfully
Zicom Group Limited

G L Sim
Chairman.